Memantine in the treatment of mild-to-moderate Alzheimer's disease
Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the e...
Saved in:
Published in | Expert opinion on pharmacotherapy Vol. 8; no. 2; p. 203 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
01.02.2007
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calcium during a sustained release of glutamate. Preclinical studies of memantine reveal that it has the potential to improve memory and learning processes after impairment has occurred, as well as to prevent further neuronal damage. Although memantine has been considered for the treatment of earlier AD, it has not yet been approved for this. Randomized controlled trials of memantine in the treatment of mild-to-moderate AD have demonstrated small treatment effects in measures of cognition, global assessment and behavior favoring the use of memantine. However, the differences between treatment groups were not consistently significant. Two ongoing long-term trials are further investigating the efficacy of memantine in the treatment of mild-to-moderate AD. |
---|---|
AbstractList | Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calcium during a sustained release of glutamate. Preclinical studies of memantine reveal that it has the potential to improve memory and learning processes after impairment has occurred, as well as to prevent further neuronal damage. Although memantine has been considered for the treatment of earlier AD, it has not yet been approved for this. Randomized controlled trials of memantine in the treatment of mild-to-moderate AD have demonstrated small treatment effects in measures of cognition, global assessment and behavior favoring the use of memantine. However, the differences between treatment groups were not consistently significant. Two ongoing long-term trials are further investigating the efficacy of memantine in the treatment of mild-to-moderate AD. |
Author | Cosman, Kelly M Porsteinsson, Anton P Boyle, Lisa L |
Author_xml | – sequence: 1 givenname: Kelly M surname: Cosman fullname: Cosman, Kelly M email: Kelly_Cosman@urmc.rochester.edu organization: University of Rochester School of Medicine, Alzheimer's Disease Care Research and Education Program (AD-CARE), Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620, USA. Kelly_Cosman@urmc.rochester.edu – sequence: 2 givenname: Lisa L surname: Boyle fullname: Boyle, Lisa L – sequence: 3 givenname: Anton P surname: Porsteinsson fullname: Porsteinsson, Anton P |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17257090$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j7tOxDAURC0EYh_QUyF3VA62Y_va5bLiJS2igXrlxDdao9hZJaaArycSoClGp5mjWZHTPGQk5ErwSmgBt0IZPcdUtpKV5PUJWQpQioExZkFW0_TBueROq3OyECA1cMeX5O4Fk88lZqQx03JAWkb0JWEudOhoin1gZWBpCDj6gnTTfx8wJhxvJhrihH7CC3LW-X7Cy79ek_eH-7ftE9u9Pj5vNzvWKsULs8ZpWc9aw3XwrmlrZbxrobZd47CprQCrAYB36PXM0MoAzvLWBmel9XJNrn93j59NwrA_jjH58Wv_f0b-AFe3Sqc |
CitedBy_id | crossref_primary_10_1016_j_expneurol_2009_04_006 crossref_primary_10_1021_jm301255m crossref_primary_10_1038_sj_bjp_0707446 crossref_primary_10_1021_np100746w crossref_primary_10_3858_emm_2010_42_5_040 crossref_primary_10_1002_anie_201101599 crossref_primary_10_1038_s41598_022_22963_x crossref_primary_10_1155_2016_7898093 crossref_primary_10_1007_s40263_015_0257_8 crossref_primary_10_1016_j_pneurobio_2009_07_009 crossref_primary_10_1021_jm100793t crossref_primary_10_1097_FBP_0000000000000296 crossref_primary_10_1002_gps_1634 crossref_primary_10_1016_j_neuropharm_2020_108342 crossref_primary_10_1186_1471_2202_9_S2_S14 crossref_primary_10_1208_s12248_008_9056_1 crossref_primary_10_1016_j_neurobiolaging_2008_08_009 crossref_primary_10_1517_13543784_2011_601740 crossref_primary_10_31363_2313_7053_2018_2_117_124 crossref_primary_10_1002_med_21323 crossref_primary_10_1016_j_neuint_2007_10_003 crossref_primary_10_1021_jm701394a crossref_primary_10_1002_ange_201101599 crossref_primary_10_1002_anie_200805426 crossref_primary_10_1016_j_bmc_2008_07_045 crossref_primary_10_2174_1871527321666220418125057 crossref_primary_10_1016_j_neuropharm_2011_01_035 crossref_primary_10_1002_med_21440 crossref_primary_10_1016_j_neuroscience_2012_06_028 crossref_primary_10_1021_jm200036n crossref_primary_10_3389_fnmol_2020_00124 crossref_primary_10_1038_nrn3531 crossref_primary_10_1523_JNEUROSCI_1204_14_2014 crossref_primary_10_1111_j_1742_7843_2008_00210_x crossref_primary_10_2217_17520363_3_1_5 crossref_primary_10_1002_ange_200805426 crossref_primary_10_4264_numa_71_379 crossref_primary_10_3390_cancers12010146 crossref_primary_10_17116_jnevro2017117101136_143 crossref_primary_10_1155_2012_789671 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1517/14656566.8.2.203 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1744-7666 |
ExternalDocumentID | 17257090 |
Genre | Journal Article Review |
GroupedDBID | --- 00X 03L 0BK 0R~ 29G 4.4 53G 5GY AAOUU AAPWH ABBAB ABEIZ ABJNI ABJYH ABLIJ ABLKL ABXYU ACGFS ADCVX ADRBQ ADTOD AECIN AENEX AEOZL AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BLEHA CAZVN CCCUG CGR CS3 CUY CVF DASJU DAWQK DKSSO DU5 EBS ECM EIF EJD F5P HZ~ KRBQP KSSTO KUULJ KWAYT KYCEM LJTGL LSO M44 M4Z NPM O9- P2P RNANH TBQAZ TERGH TFDNU TFL TFW TZHSB V1S ~1N |
ID | FETCH-LOGICAL-c440t-869523570605da9bc346a9c738fb9eb3817857770fea5eb37c2d7980c8d9828a2 |
IngestDate | Thu May 23 23:12:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c440t-869523570605da9bc346a9c738fb9eb3817857770fea5eb37c2d7980c8d9828a2 |
PMID | 17257090 |
ParticipantIDs | pubmed_primary_17257090 |
PublicationCentury | 2000 |
PublicationDate | 2007-02-01 |
PublicationDateYYYYMMDD | 2007-02-01 |
PublicationDate_xml | – month: 02 year: 2007 text: 2007-02-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Expert opinion on pharmacotherapy |
PublicationTitleAlternate | Expert Opin Pharmacother |
PublicationYear | 2007 |
SSID | ssj0020954 |
Score | 2.0408266 |
SecondaryResourceType | review_article |
Snippet | Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 203 |
SubjectTerms | Aged Alzheimer Disease - drug therapy Calcium - metabolism Drug Therapy, Combination Excitatory Amino Acid Antagonists - therapeutic use Humans Memantine - adverse effects Memantine - metabolism Memantine - pharmacology Memantine - therapeutic use Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors |
Title | Memantine in the treatment of mild-to-moderate Alzheimer's disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17257090 |
Volume | 8 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFLYKXLhMwGAbv-TDBIfiLk2c2D62FRMaA_VQJG7gxI7IVJKKhEP563lOnKTtYNp2iZI4iSJ_Ly_vPb_3PYS-xp4UTuj2iaKKEco8jwjpucSN-57SVLMoNgH9q-vg4ob-uPVvO537hayl5yLsRS9v1pX8D6pwDnA1VbL_gGzzUDgB-4AvbAFh2P4Vxlf6UZpOD7rOVmzTxs2yeTJVpMiIaXZjCCG6g-nLg07KdiksX1qa-dUk5OknuHeWpKUdmXZnltm6WCYfGGW5jZxe6ul03oZUh9m8yk_-meSy2wSWxxkYmTpJc1vfNTCdi21pWR1yYHWWsvljVGqSUUpYUPVLqfUoXxAXd1EnliQGv-tqv2-r_Uubssd7pi5u6VKY7dljiR2YWT5zqsaifx5dYc-uh9bQGuNGA16baI51yMG8pHbpGl7m2-qrGEJZe_uK01EaH5Mt9MF6DXhQicA26uh0B52MK3DmZ3jSVtHlZ_gEj1tC8vlHNGzkBCcpBihxIyc4i_GqnOBGTk5zbKVkF918P5-MLojtnUEiSp2C8ED4hsnIAXdVSRFGHg2kiJjH41Do0PAycp8x5sRa-nDMIlcxwZ2IKwFOuHT30HqapfozwpSZpgixiqSAR4eC-0oEPJTa5NGBev-CPlVzczerCFLu6lnbf3fkAG22gnWINmL4IvURmHdFeFxi9Ap-Z05f |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Memantine+in+the+treatment+of+mild-to-moderate+Alzheimer%27s+disease&rft.jtitle=Expert+opinion+on+pharmacotherapy&rft.au=Cosman%2C+Kelly+M&rft.au=Boyle%2C+Lisa+L&rft.au=Porsteinsson%2C+Anton+P&rft.date=2007-02-01&rft.eissn=1744-7666&rft.volume=8&rft.issue=2&rft.spage=203&rft_id=info:doi/10.1517%2F14656566.8.2.203&rft_id=info%3Apmid%2F17257090&rft_id=info%3Apmid%2F17257090&rft.externalDocID=17257090 |